Age-dependent association between protein expression of the embryonic stem cell marker cripto-1 and survival of glioblastoma patients

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 732-741

  Tysnes, Berit B ^a   Sætran, Hege A ^b   Mørk, Sverre J ^a,b   Margaryan, Naira V ^c   Eide, Geir E ^a,b   Petersen, Kjell ^d   Strizzi, Luigi ^c   Hendrix, Mary J C ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Uni Research AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CRIPTO 1; GROWTH FACTOR; LEFT RIGHT DETERMINATION FACTOR; PROTEIN NODAL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR BIOPSY; VERY ELDERLY;

EID: 84891819082     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13427     Document Type: Article

References (83)

1. Ohgaki H and Kleihues P (2005). Epidemiology and etiology of gliomas. Acta Neuropathol 109, 93-108.
2. Giese A, Bjerkvig R, Berens ME, and Westphal M (2003). Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624-1636.
3. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, and Stupp R (2004). Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10, 1871-1874.
4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
6. Reardon DA and Wen PY (2006). Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11, 152-164.
7. Wen PY and Kesari S (2008). Malignant gliomas in adults. N Engl J Med 359, 492-507.
8. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
9. Tran B and Rosenthal MA (2010). Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17, 417-421.
10. Postovit LM, Costa FF, Bischof JM, Seftor EA, Wen B, Seftor RE, Feinberg AP, Soares MB, and Hendrix MJ (2007). The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J Cell Biochem 101, 908-917.
11. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, Nickoloff BJ, Topczewski J, and Hendrix MJ (2006). Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 12, 925-932.
12. Reya T, Morrison SJ, Clarke MF, and Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
13. Pardal R, Clarke MF, and Morrison SJ (2003). Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3, 895-902.
14. Tysnes BB and Bjerkvig R (2007). Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta 1775, 283-297.
15. Lobo NA, Shimono Y, Qian D, and Clarke MF (2007). The biology of cancer stem cells. Annu Rev Cell Dev Biol 23, 675-699.
16. Visvader JE (2011). Cells of origin in cancer. Nature 469, 314-322.
17. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, et al. (2008). Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26, 3015-3024.
18. Yu Y, Ramena G, and Elble RC (2012). The role of cancer stem cells in relapse of solid tumors. Front Biosci (Elite Ed) 4, 1528-1541.
19. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, et al. (2008). Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14, 8205-8212.
20. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, and Herold-Mende CC (2008). Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14, 123-129.
21. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, and Clarke MF (2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356, 217-226.
22. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, and Weinberg RA (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40, 499-507.
23. Glinsky GV (2008). "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 26, 2846-2853.
24. Vallier L, Reynolds D, and Pedersen RA (2004). Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev Biol 275, 403-421.
25. Vallier L, Alexander M, and Pedersen RA (2005). Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 118, 4495-4509.
26. James D, Levine AJ, Besser D, and Hemmati-Brivanlou A (2005). TGFbeta/ activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132, 1273-1282.
27. Saha S, Ji L, de Pablo JJ, and Palecek SP (2008). TGFβ/Activin/Nodal pathway in inhibition of human embryonic stem cell differentiation by mechanical strain. Biophys J 94, 4123-4133.
28. Schier AF and Shen MM (2000). Nodal signalling in vertebrate development. Nature 403, 385-389.
29. Schier AF (2003). Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 19, 589-621.
30. Shen MM (2007). Nodal signaling: developmental roles and regulation. Development 134, 1023-1034.
31. Schier AF (2009). Nodal morphogens. Cold Spring Harb Perspect Biol 1, a003459.
32. Bianco C, Strizzi L, Normanno N, Khan N, and Salomon DS (2005). Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 67, 85-133.
33. Strizzi L, Bianco C, Normanno N, and Salomon D (2005). Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene 24, 5731-5741.
34. Chen C and Shen MM (2004). Two modes by which Lefty proteins inhibit nodal signaling. Curr Biol 14, 618-624.
35. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C, Seftor RE, Seftor EA, and Hendrix MJ (2009). Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 4, 67-78.
36. Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, Cheng YY, Liu LW, Wei HW, and Lee HM (2010). Nodal promotes growth and invasion in human gliomas. Oncogene 29, 3110-3123.
37. Bianco C and Salomon DS (2010). Targeting the embryonic gene Cripto-1 in cancer and beyond. Expert Opin Ther Pat 20, 1739-1749.
38. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, et al. (2012). Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res 14, R75.
39. Sakariassen PØ, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, et al. (2006). Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 103, 16466-16471.
40. Wang J, Miletic H, Sakariassen PØ, Huszthy PC, Jacobsen H, Brekkå N, Li X, Zhao P, Mørk S, Chekenya M, et al. (2009). A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 9, 465.
41. Johannessen TC, Wang J, Skaftnesmo KO, Sakariassen PØ, Enger PØ, Petersen K, Øyan AM, Kalland KH, Bjerkvig R, and Tysnes BB (2009). Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol 35, 380-393.
42. Bjerkvig R, Tønnesen A, Laerum OD, and Backlund EO (1990). Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg 72, 463-475.
43. Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen PØ, Miletic H, Thorsen F, and Bjerkvig R (2012). In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol 14, 979-993.
44. Engebraaten O, Hjortland GO, Hirschberg H, and Fodstad O (1999). Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 90, 125-132.
45. Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, and Engebraaten O (2003). Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 105, 49-57.
46. Thorsen F, Ersland L, Nordli H, Enger PO, Huszthy PC, Lundervold A, Standnes T, Bjerkvig R, and Lund-Johansen M (2003). Imaging of experimental rat gliomas using a clinical MR scanner. J Neurooncol 63, 225-231.
47. Halvorsen OJ, Oyan AM, Bø TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, et al. (2005). Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol 26, 329-336.
48. Petersen K, Oyan AM, Rostad K, Olsen S, Bø TH, Salvesen HB, Gjertsen BT, Bruserud O, Halvorsen OJ, Akslen LA, et al. (2007). Comparison of nucleic acid targets prepared from total RNA or poly (A) RNA for DNA oligonucleotide microarray hybridization. Anal Biochem 366, 46-58.
49. Stavrum AK, Petersen K, Jonassen I, and Dysvik B (2008). Analysis of geneexpression data using J-Express. Curr Protoc Bioinformatics Chapter 7, Unit 7. 3.
50. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, and Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109.
51. Yu L, Harms PW, Pouryazdanparast P, Kim DS, Ma L, and Fullen DR (2010). Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Mod Pathol 23, 1209-1214.
52. Kaplan E and Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53, 457-481.
53. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50, 163-170.
54. Cox D (1972). Regression models and life tables. J R Stat Soc Series B 34, 187-220.
55. Bianco C, Rangel MC, Castro NP, Nagaoka T, Rollman K, Gonzales M, and Salomon DS (2010). Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 177, 532-540.
56. Mallikarjuna K, Vaijayanthi P, and Krishnakumar S (2007). Cripto-1 expression in uveal melanoma: an immunohistochemical study. Exp Eye Res 84, 1060-1066.
57. De Luca A, Lamura L, Strizzi L, Roma C, D'Antonio A, Margaryan N, Pirozzi G, Hsu MY, Botti G, Mari E, et al. (2011). Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer 105, 1030-1038.
58. Miyoshi N, Ishii H, Mimori K, Sekimoto M, Doki Y, and Mori M (2010). TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer. Int J Oncol 36, 563-568.
59. Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, Zhang GG, Hu Y, Lu AP, Li JY, et al. (2008). Positive association of up-regulated Cripto-1 and downregulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology 52, 560-568.
60. Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, Xing PX, and Gillett DJ (2007). Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol 33, 438-443.
61. Yoon HJ, Hong JS, Shin WJ, Lee YJ, Hong KO, Lee JI, Hong SP, and Hong SD (2011). The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma. Oral Oncol 47, 1023-1031.
62. Hueng DY, Lin GJ, Huang SH, Liu LW, Ju DT, Chen YW, Sytwu HK, Chang C, Huang SM, Yeh YS, et al. (2011). Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J Neurooncol 104, 21-31.
63. Bianco C, Adkins HB, Wechselberger C, Seno M, Normanno N, De Luca A, Sun Y, Khan N, Kenney N, Ebert A, et al. (2002). Cripto-1 activates Nodal-and ALK4-dependent and-independent signaling pathways in mammary epithelial cells. Mol Cell Biol 22, 2586-2597.
64. Bianco C, Strizzi L, Rehman A, Normanno N, Wechselberger C, Sun Y, Khan N, Hirota M, Adkins H, Williams K, et al. (2003). A Nodal-and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 63, 1192-1197.
65. Bianco C, Mysliwiec M, Watanabe K, Mancino M, Nagaoka T, Gonzales M, and Salomon DS (2008). Activation of a Nodal-independent signaling pathway by Cripto-1 mutants with impaired activation of a Nodal-dependent signaling pathway. FEBS Lett 582, 3997-4002.
66. Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, and Gray PC (2009). Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 28, 2324-2336.
67. Gray PC and Vale W (2012). Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. FEBS Lett 586, 1836-1845.
68. Nagaoka T, Karasawa H, Castro NP, Rangel MC, Salomon DS, and Bianco C (2012). An evolving web of signaling networks regulated by Cripto-1. Growth Factors 30, 13-21.
69. Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y, Sanicola M, et al. (2004). Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 201, 266-276.
70. Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, Guedez L, Salloum R, Ginsburg E, Sun Y, et al. (2005). Role of human Cripto-1 in tumor angiogenesis. J Natl Cancer Inst 97, 132-141.
71. Strizzi L, Bianco C, Hirota M, Watanabe K, Mancino M, Hamada S, Raafat A, Lawson S, Ebert AD, D'Antonio A, et al. (2007). Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. J Pathol 211, 36-44.
72. Bianco C, Cotten C, Lonardo E, Strizzi L, Baraty C, Mancino M, Gonzales M, Watanabe K, Nagaoka T, Berry C, et al. (2009). Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol 175, 2146-2158.
73. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. (2006). Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173.
74. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110.
75. Lee HK, Xiang C, Cazacu S, Finniss S, Kazimirsky G, Lemke N, Lehman NL, Rempel SA, Mikkelsen T, and Brodie C (2008). GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis. Neuro Oncol 10, 236-243.
76. Miharada K, Karlsson G, Rehn M, Rorby E, Siva K, Cammenga J, and Karlsson S (2012). Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1α in the hypoxic bone marrow niche. Ann N Y Acad Sci 1266, 55-62.
77. Wu MJ, Jan CI, Tsay YG, Yu YH, Huang CY, Lin SC, Liu CJ, Chen YS, Lo JF, and Yu CC (2010). Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer 9, 283.
78. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, et al. (2003). Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112, 575-587.
79. Xing PX, Hu XF, Pietersz GA, Hosick HL, and McKenzie IF (2004). Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 64, 4018-4023.
80. Hu XF, Li J, Yang E, Vandervalk S, and Xing PX (2007). Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 96, 918-927.
81. Parisi S, D'Andrea D, Lago CT, Adamson ED, Persico MG, and Minchiotti G (2003). Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells. J Cell Biol 163, 303-314.
82. Parish CL, Parisi S, Persico MG, Arenas E, and Minchiotti G (2005). Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease. Stem Cells 23, 471-476.
83. Lonardo E, Parish CL, Ponticelli S, Marasco D, Ribeiro D, Ruvo M, De Falco S, Arenas E, and Minchiotti G (2010). A small synthetic cripto blocking peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson's disease. Stem Cells 28, 1326-1337.